Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Capital Expenditures (2020 - 2025)

Vivos Therapeutics' Capital Expenditures history spans 6 years, with the latest figure at $1.5 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $1.5 million for Q4 2025, up 827.88% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 312.15% YoY), and the annual figure for FY2025 was $2.3 million, up 312.15%.
  • Capital Expenditures for Q4 2025 was $1.5 million at Vivos Therapeutics, up from -$83000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q4 2025 to a low of -$1.9 million in Q4 2021.
  • The 5-year median for Capital Expenditures is $165000.0 (2024), against an average of $234882.4.
  • Peak annual rise in Capital Expenditures hit 16701.23% in 2021, while the deepest fall reached 8174.3% in 2021.
  • Year by year, Capital Expenditures stood at -$1.9 million in 2021, then soared by 110.5% to $200000.0 in 2022, then tumbled by 75.0% to $50000.0 in 2023, then skyrocketed by 230.0% to $165000.0 in 2024, then soared by 827.88% to $1.5 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $1.5 million, -$83000.0, and $771000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.